Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids

• References

• 1 Samama MM, Gerotziafas GT. Evaluation of the pharmacokological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Res 2003; 109: 1-11.
• 2 Donat F, Duret JP, Santoni A. et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 2002; 41 (Suppl. 02) (Suppl) 1-9.
• 3 Bates SM, Greer IA, Hirsh J. et al. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 627S-644S.
• 4 Gerhardt A, Scharf RE, Beckmann MW. et al. Prothrombin and Factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342: 374-380.
• 5 Mazzolai L, Hohlfeld P, Spertini F. et al. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood 2006; 108: 1569-1570.
• 6 Dempfle CH. Minor transplacental passage of fondaparinux in vivo. N Engl J Med 2004; 350: 1914-1915.
• 7 Lagrange F, Vergnes C, Brun JL. et al. Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra) in the dually perfused human cotyledon in vitro. Thromb Haemost 2002; 87: 831-835.